Home/Blog/Trading Ideas/Beyond Natural Selection

Beyond Natural Selection

26 April 2019 in Trading Ideas

The first person to live to 150 has already been born

Our biological destiny is transforming like never before. In 1900, you would be lucky to live for 50 years; today, 50 is arguably the new 30. Advances in science, medicine, and technology have not only prolonged our lives but they’ve allowed us to stay healthy into our 70s and beyond. Our track record in beating once fatal diseases is also improving dramatically: The five-year survival rate for men with prostate cancer has risen from 69 percent in the 1970s to 100 percent in 2007.

A brave new world of medicine

Many of today’s most promising diagnostics and treatments are occurring at the intersection of biology, physics and digital technology.

We have started to understand how to edit human genes and to make replacement organs using 3D printing technology. Surgeons rely on robotic systems to perform complex operations, while researchers mine big data to drive drug discovery. Advances in genomics are swinging the doors wide open to precision medicine, allowing us to apply therapies targeting diseases at the molecular level rather than one-size-fits-all treatments that only alleviate symptoms.

Human Evolution Innovation Exposure

Human Evolution Innovation Exposure

Performance of GDNA

As we reshape our biological evolution through the convergence of multiple domains, it’s an opportune moment to invest in innovations that reimagine medicine and healthcare. The Goldman Sachs GDNA ETF, a component of our Next Wave of Innovation portfolio, allows you to gain exposure to businesses that are ushering in medicine and healthcare’s next frontiers.


Invest in GDNA